Lucas Kas Vitzthum

Lucas Kas Vitzthum

Auto-generated profile, based on publicly available information

Lucas Kas Vitzthum

Department of Radiation Oncology, Stanford University, Stanford, California

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
PRPaul Riviere
Paul Riviere
ELElaine Luterstein
Elaine Luterstein
AKAbhishek Kumar
Abhishek Kumar
LVLucas K. Vitzthum
Lucas K. Vitzthum
RDRishi Deka
Rishi Deka
BRBrent S. Rose
Brent S. Rose

26 June 2023 in IEEE Transactions on Pattern Analysis and Machine Intelligence
Verified
Journal Article
Closed access
YCYizheng Chen
Yizheng Chen
LYLequan Yu
Lequan Yu
JWJen-Yeu Wang
Jen-Yeu Wang
NPNeil Panjwani
Neil Panjwani
JOJean-Pierre Obeid
Jean-Pierre Obeid
Lei XingLei Xing
Lei Xing
Defining the loss function is an important part of neural network design and critically determines the success of deep learning modeling. A significant shortcoming of the conventional loss functions is that they weight all regions in the input image volume equally, despite the fact that the system is known to be heterogeneous (i.e., some regions can achieve high prediction performance more easily than others). Here, we introduce a region-specific loss to lift the implicit assumption of homogeneous weighting for better learning. We divide the entire volume into multiple sub-regions, each with an individualized loss constructed for optimal local performance. Effectively, this scheme imposes higher weightings on the sub-regions that are more difficult to segment, and vice versa. Furthermore, the regional false positive and false negative errors are computed for each input image during a training step and the regional penalty is adjusted accordingly to enhance the overall accuracy of the prediction. Using different public and in-house medical image datasets, we demonstrate that the proposed regionally adaptive loss paradigm outperforms conventional methods in the multi-organ segmentations, without any modification to the neural network architecture or additional data preparation.

1 July 2020 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
LVLucas K Vitzthum
Lucas K Vitzthum
PRPaul Riviere
Paul Riviere
PSPaige Sheridan
Paige Sheridan
VNVinit Nalawade
Vinit Nalawade
RDRishi Deka
Rishi Deka
JMJames D Murphy
James D Murphy
Background: Although opioids play a critical role in the management of cancer pain, the ongoing opioid epidemic has raised concerns regarding their persistent use and abuse. We lack data-driven tools in oncology to understand the risk of adverse opioid-related outcomes. This project seeks to identify clinical risk factors and create a risk score to help identify patients at risk of persistent opioid use and abuse.Methods: Within a cohort of 106 732 military veteran cancer survivors diagnosed between 2000 and 2015, we determined rates of persistent posttreatment opioid use, diagnoses of opioid abuse or dependence, and admissions for opioid toxicity. A multivariable logistic regression model was used to identify patient, cancer, and treatment risk factors associated with adverse opioid-related outcomes. Predictive risk models were developed and validated using a least absolute shrinkage and selection operator regression technique.Results: The rate of persistent opioid use in cancer survivors was 8.3% (95% CI = 8.1% to 8.4%); the rate of opioid abuse or dependence was 2.9% (95% CI = 2.8% to 3.0%); and the rate of opioid-related admissions was 2.1% (95% CI = 2.0% to 2.2%). On multivariable analysis, several patient, demographic, and cancer and treatment factors were associated with risk of persistent opioid use. Predictive models showed a high level of discrimination when identifying individuals at risk of adverse opioid-related outcomes including persistent opioid use (area under the curve [AUC] = 0.85), future diagnoses of opioid abuse or dependence (AUC = 0.87), and admission for opioid abuse or toxicity (AUC = 0.78).Conclusion: This study demonstrates the potential to predict adverse opioid-related outcomes among cancer survivors. With further validation, personalized risk-stratification approaches could guide management when prescribing opioids in cancer patients.

3 February 2021 in JCO Oncology Practice
Verified
Journal Article
Closed access
LVLucas K. Vitzthum
Lucas K. Vitzthum
VNVinit Nalawade
Vinit Nalawade
PRPaul Riviere
Paul Riviere
WSWhitney Sumner
Whitney Sumner
TNTyler Nelson
Tyler Nelson
JMJames D. Murphy
James D. Murphy
PURPOSE: Minority race and lower socioeconomic status are associated with lower rates of opioid prescription and undertreatment of pain in multiple noncancer healthcare settings. It is not known whether these differences in opioid prescribing exist among patients undergoing cancer treatment. METHODS AND MATERIALS: This observational cohort study involved 33,872 opioid-naive patients of age > 65 years undergoing definitive cancer treatment. We compared rates of new opioid prescriptions by race or ethnicity and socioeconomic status controlling for differences in baseline patient, cancer, and treatment factors. To evaluate downstream impacts of opioid prescribing and pain management, we also compared rates of persistent opioid use and pain-related emergency department (ED) visits. RESULTS: Compared with non-Hispanic White patients, the covariate-adjusted odds of receiving an opioid prescription were 24.9% (95% CI, 16.0 to 33.9, P < .001) lower for non-Hispanic Blacks, 115.0% (84.7 to 150.3, P < .001) higher for Asian–Pacific Islanders, and not statistically different for Hispanics (−1.0 to 14.0, P = .06). There was no significant association between race or ethnicity and persistent opioid use or pain-related ED visits. Patients living in a high-poverty area had higher odds (53.9% [25.4 to 88.8, P < .001]) of developing persistent use and having a pain-related ED visit (39.4% [16.4 to 66.9, P < .001]). CONCLUSION: For older patients with cancer, rates of opioid prescriptions and pain-related outcomes significantly differed by race and area-level poverty. Non-Hispanic Black patients were associated with a significantly decreased likelihood of receiving an opioid prescription. Patients from high-poverty areas were more likely to develop persistent opioid use and have a pain-related ED visit.

15 November 2022 in British Journal of Radiology
Verified
Journal Article
Closed access
ZHZhiqiang Hu
Zhiqiang Hu
MBMatthew Bieniosek
Matthew Bieniosek
VFValentina Ferri
Valentina Ferri
AIAndrei Iagaru
Andrei Iagaru
NKNataliya Kovalchuk
Nataliya Kovalchuk
MSMurat Surucu
Murat Surucu
Objectives: In this study, we characterise the imaging-mode performance of the positron emission tomography (PET) subsystem of the RefleXion X1 machine using the NEMA NU-2 2018 standard. Methods: The X1 machine consists of two symmetrically opposing 900 arcs of PET detectors incorporated into the architecture of a ring-gantry linear accelerator rotating up to 60 RPM. PET emissions from a tumour are detected by the PET detectors and used to guide the delivery of radiation beam. Imaging performance of the PET subsystem on X1 machine was evaluated based on sensitivity of the PET detectors, spatial resolution, count-loss performance, image quality, and daily system performance check. Results: PET subsystem sensitivity was measured as 0.183 and 0.161 cps/kBq at the center and off-center positions, respectively. Spatial resolution: average FWHM values of 4.3, 5.1, and 6.7 mm for the point sources at 1, 10, and 20 cm off center, respectively were recorded. For count loss, max NECR: 2.63 kcps, max true coincidence rate: 5.56 kcps, and scatter fraction: 39.8%. The 10 mm sphere was not visible. Image-quality contrast values were: 29.6%, 64.9%, 66.5%, 81.8%, 81.2%, and background variability: 14.8%, 12.4%, 10.3%, 8.8%, 8.3%, for the 13, 17, 22, 28, 37 mm sphere sizes, respectively. Conclusions: When operating in an imaging mode, the spatial resolution and image contrast of the X1 PET subsystem were comparable to those of typical diagnostic imaging systems for large spheres, while the sensitivity and count rate were lower due to the significantly smaller PET detector area in the X1 system. Clinical efficacy when used in BgRT remains to be validated. Advances in knowledge: This is the first performance evaluation of the PET subsystem on the novel BgRT machine. The dual arcs rotating PET subsystem on RefleXion X1 machine performance is comparable to those of the typical diagnostic PET system based on the spatial resolution and image contrast for larger spheres.

24 December 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
LVLucas K. Vitzthum
Lucas K. Vitzthum
MSMurat Surucu
Murat Surucu
MGMichael F. Gensheimer
Michael F. Gensheimer
NKNataliya Kovalchuk
Nataliya Kovalchuk
BHBin Han
Bin Han
AGAurelie Garant
Aurelie Garant